ArticleMolecular and cellular biochemistry2017
Methylene blue decreases mitochondrial lysine acetylation in the diabetic heart.
Article in Molecular and cellular biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Integrated meta-analysis and network pharmacology analysis: evaluation of Zhigancao decoction as treatment for diabetic cardiomyopathy.Frontiers in cardiovascular medicine · 2025Pooled it
- Rheology of Aqueous Solutions in the Presence of Proton Exchange Membrane: Surface Tension.Polymers · 2025Article
- Methylene blue reduces monoamine oxidase expression and oxidative stress in human cardiovascular adipose tissue.Molecular and cellular biochemistry · 2025Article
- Proteomics of the heart.Physiological reviews · 2024Review
- Evaluation of topical methylene blue nanoemulsion for wound healing in diabetic mice.Pharmaceutical biology · 2023Article
- CycloZ Improves Hyperglycemia and Lipid Metabolism by Modulating Lysine Acetylation in KK-Ay Mice.Diabetes & metabolism journal · 2023Article
- Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2021Review
- NADCirculation. Heart failure · 2021Article
- Metabolic regulation of endothelial SK channels and human coronary microvascular function.International journal of cardiology · 2020Article
- Mitochondrial NADAntioxidants & redox signaling · 2019Review
- Apoptosis inducing factor deficiency causes retinal photoreceptor degeneration. The protective role of the redox compound methylene blue.Redox biology · 2019Article
- Sirt3 Impairment and SOD2 Hyperacetylation in Vascular Oxidative Stress and Hypertension.Circulation research · 2017Article
- Possible Treatment of Topical Steroid Withdrawal with Methylene Blue Case Report: Implications for Mitochondrial Pathology.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy is preceded by mitochondrial alterations, and progresses to heart failure. We studied whether treatment with methylene blue (MB), a compound that was reported to serve as an alternate electron carrier within the mitochondrial electron transport chain (ETC), improves mitochondrial metabolism and cardiac function in type 1 diabetes. MB was administered at 10 mg/kg/day to control and diabetic rats. Both echocardiography and hemodynamic studies were performed to assess cardiac function. Mitochondrial studies comprised the measurement of oxidative phosphorylation and specific activities of fatty acid oxidation enzymes. Proteomic studies were employed to compare the level of lysine acetylation on cardiac mitochondrial proteins between the experimental groups. We found that MB facilitates NADH oxidation, increases NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.